Bioresources and Bioprocessing· 2026Q1
CYP1B1 is a potential target of kaempferol in renal fibrosis: a multi‑omics and single‑cell transcriptomics study
- 0citations
- Q1SCImago
- 2026year
Short summary
Kaempferol (Kae) may treat renal fibrosis (RF) by targeting CYP1B1, a gene found to be upregulated in late-stage fibroblasts and smooth muscle cells, and its virtual knockdown worsened fibrosis markers.
AI-generated from the title and abstract; the full text is not read.
Key points
- Six core genes (VCAM1, NFKBIA, SFN, CCL5, CYP1B1, AXL) were identified as targets of kaempferol in renal fibrosis, with CYP1B1 acting as an upstream regulatory hub.
- CYP1B1 is specifically localized to smooth muscle cells and fibroblasts and is upregulated during late-stage fibroblast-to-myofibroblast differentiation.
- Virtual knockdown of CYP1B1 led to the upregulation of 46 genes associated with fibrosis, including cell adhesion and ECM remodeling.
- A diagnostic model based on the six core genes achieved AUCs of 0.889 (training) and 0.759 (external validation).
AI-generated from the title and abstract; the full text is not read.
Abstract
Abstract Background Renal fibrosis (RF) is a progressive and irreversible pathological process for which effective treatments are limited. This study explores the molecular targets and mechanisms through which kaempferol (Kae) ameliorates RF, with particular emphasis on cytochrome P450 1B1 (CYP1B1). Methods Using a combination of transcriptomic profiling, weighted gene co‑expression network analysis (WGCNA), multi‑algorithm machine learning [least absolute shrinkage and selection operator (LASSO), support vector machine‑recursive feature elimination (SVM‑RFE), and Random Forest], and single‑cell transcriptomics, we identified the core targets of Kae intervention in RF. shapley additive explanations (SHAP) analysis evaluated gene contributions to the predictive model, while cell‑type identification by estimating relative subsets of RNA transcripts (CIBERSORT) estimated the immune microenvironment. The cell type-specific distribution of core targets was further characterized through single-cell RNA sequencing (scRNA-seq), and the scTenifoldKnk (a machine learning-based virtual gene knockout tool) algorithm simulated the effects of CYP1B1 loss-of-function on fibroblast activation and extracellular matrix (ECM) deposition. Finally, molecular docking was performed to predict the binding conformations of kaempferol with the proteins encoded by the six prioritized genes. Results Six core genes (VCAM1, NFKBIA, SFN, CCL5, CYP1B1, and AXL) were identified from 25 Kae-RF-related genes, with CYP1B1 as an upstream regulatory hub. Immune infiltration analysis revealed increased plasma cells and eosinophils, alongside decreased M0/M1 macrophages and activated NK cells. Single-cell analysis localized CYP1B1 to smooth muscle cells and fibroblasts, with significant upregulation during late-stage fibroblast-to-myofibroblast differentiation. Virtual knockdown of CYP1B1 upregulated 46 genes associated with fibrosis-related biological processes, including cell adhesion, G protein-coupled receptor (GPCR) signaling, ion transport, and cytoskeletal remodeling. The six-gene diagnostic model achieved area under the curves (AUCs) of 0.889 (training) and 0.759 (external validation). Molecular docking showed favorable Kae–CYP1B1 binding (− 6.5 kcal/mol). Conclusion CYP1B1 may serve as a potential functional target of Kae in RF, likely through modulation of fibroblast activation and ECM remodeling. These findings are hypothesis‑generating and provide a computational basis for future experimental validation of CYP1B1‑targeted strategies in RF.
The authors' abstract, as published at the source. Bioresources and Bioprocessing, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Nephrology
NephrologyMedicine